1. Home
  2. EHAB vs KROS Comparison

EHAB vs KROS Comparison

Compare EHAB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhabit Inc.

EHAB

Enhabit Inc.

HOLD

Current Price

$13.62

Market Cap

690.9M

Sector

Health Care

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$10.71

Market Cap

584.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHAB
KROS
Founded
2014
2015
Country
United States
United States
Employees
10800
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
690.9M
584.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
EHAB
KROS
Price
$13.62
$10.71
Analyst Decision
Hold
Buy
Analyst Count
5
8
Target Price
$13.84
$22.25
AVG Volume (30 Days)
2.3M
415.8K
Earning Date
03-04-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
97.11
146.00
EPS
N/A
2.30
Revenue
$1,060,000,000.00
$243,864,000.00
Revenue This Year
$6.42
N/A
Revenue Next Year
$4.88
$727.07
P/E Ratio
N/A
$4.83
Revenue Growth
2.44
N/A
52 Week Low
$6.47
$9.12
52 Week High
$13.66
$22.55

Technical Indicators

Market Signals
Indicator
EHAB
KROS
Relative Strength Index (RSI) 78.33 22.11
Support Level $10.79 $10.49
Resistance Level $13.65 $15.21
Average True Range (ATR) 0.03 0.66
MACD -0.11 0.03
Stochastic Oscillator 43.75 6.56

Price Performance

Historical Comparison
EHAB
KROS

About EHAB Enhabit Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: